

Arndt Stahler

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7679570/arndt-stahler-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

233
citations

6
h-index

15
g-index

35
ext. papers

355
ext. citations

3.8
avg, IF

2.21
L-index

#	Paper	IF	Citations
25	Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. <i>Annals of Oncology</i> , 2016 , 27, 1746-53	10.3	127
24	Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). <i>International Journal of Cancer</i> , 2016 , 138, 739-46	7.5	25
23	Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110). <i>Journal of Clinical Oncology</i> , 2019 , 37, 22-32	2.2	24
22	Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2017 , 28, 717-722	2.4	11
21	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). <i>Journal of Clinical Oncology</i> , 2021 , JCO2101332	2.2	8
20	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2389-2401	3.1	7
19	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2077-2087	4.9	6
18	Amphiregulin Expression Is a Predictive Biomarker for Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 6559-6567	12.9	6
17	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2020 , 137, 250-259	7.5	5
16	Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival. <i>International Journal of Cancer</i> , 2021 , 148, 1919-1927	7.5	5
15	Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21 influence on gene expression in the EGFR signaling pathway.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3593-3593	2.2	3
14	NeORAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. <i>European Journal of Cancer</i> , 2021 , 153, 86-95	7.5	2
13	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). <i>European Journal of Cancer</i> , 2020 , 137, 81-92	7.5	1
12	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). <i>International Journal of Cancer</i> , 2021 , 149, 1935-1943	7.5	1
11	Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3559-3559	2.2	0
10	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). <i>European Journal of Cancer</i> , 2021 , 147, 128-139	7.5	0
9	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). <i>European Journal of Cancer</i> , 2021 , 157, 71-80	7.5	0

8	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.. <i>Frontiers in Oncology</i> , 2022 , 12, 751453	5.3	o
7	Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV. 2022 , 39, 104		o
6	Nachwuchsaktivität der Jungen Onkologie. <i>Onkologe</i> , 2022 , 28, 67	0.1	
5	Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3584-3584	2.2	
4	High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4026-4026	2.2	
3	Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutation on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3522-3522	2.2	
2	FIRE-7-Studie (AIO-KRK-0120) 2021 , 36, 244-246	0.2	
1	FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.. <i>BMC Cancer</i> , 2022 , 22, 359	4.8	